Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines through base editing, has announced its participation in three major investor conferences in September 2025.

The company's management will engage in fireside chats at Citi's 2025 Biopharma Back to School Conference (September 3), the 2025 Wells Fargo Healthcare Conference (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 8). All presentations will be available via webcast on the company's investor relations website for 60 days following each event.

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

• Citi’s 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m. ET in Boston
• 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 1:30 p.m. ET in Boston
• H.C. Wainwright 27^th Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET in New York
  
  

The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com

FAQ

When is Beam Therapeutics (BEAM) presenting at the Citi Biopharma Conference 2025?

Beam Therapeutics will present at Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m. ET in Boston.

How can investors access Beam Therapeutics' (BEAM) September 2025 conference presentations?

Investors can access the live webcasts through Beam's investor relations website at www.beamtx.com. The presentations will be archived for 60 days after each event.

What conferences is Beam Therapeutics (BEAM) attending in September 2025?

Beam is attending three conferences: Citi's Biopharma Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), and H.C. Wainwright Global Investment Conference (Sept 8).

What time is Beam Therapeutics' (BEAM) presentation at the 2025 Wells Fargo Healthcare Conference?

Beam Therapeutics will present at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 1:30 p.m. ET in Boston.